Earnings call Viking Therapeutics reported a Q2 2026 net loss of $128.1M ($1.10/share), nearly doubling YoY due to sharply higher R&D and G&A expenses as phase III obesity trials advanced. Management ...
Chronic insomnia is a common sleep disorder that significantly impacts patients’ quality of daily life as well as physical ...
Canada wins 14 medals on Day 5: 6 gold, 2 silver, 6 bronze; Camryn Rogers is once again Commonwealth Games hammer throw ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results